Document is current
Any future updates will be listed below
-
Authors
Shephard, Adam J. https://orcid.org/0000-0003-0969-2990
Mahmood, Hanya https://orcid.org/0000-0001-7159-0368
Raza, Shan E. Ahmed https://orcid.org/0000-0002-1097-1738
Araújo, Anna Luíza Damaceno
Santos-Silva, Alan Roger
Lopes, Marcio Ajudarte
Vargas, Pablo Agustin
McCombe, Kris D.
Craig, Stephanie G.
James, Jacqueline https://orcid.org/0000-0002-6945-6060
Brooks, Jill
Nankivell, Paul https://orcid.org/0000-0003-4664-6117
Mehanna, Hisham
Khurram, Syed Ali
Rajpoot, Nasir M. https://orcid.org/0000-0001-6760-1271
- License Information
-
More Information
Article History
Received: 19 September 2024
Accepted: 14 April 2025
First Online: 20 May 2025
Competing interests
: N.M.R. is the co-founder, CEO and CSO, and a shareholder of Histofy Ltd. He is also the GSK Chair of Computational Pathology and is in receipt of research funding from GSK and AstraZeneca. S.A.K. is a shareholder of Histofy Ltd. All other authors have no competing interests to declare.
